Scientists Discover New Drug Target for Malaria - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Scientists Discover New Drug Target for Malaria


Novartis announced that its scientists have discovered a new target for antimalarial drugs. The research, published in Nature, reports on the discovery of phosphatidylinositol-4 kinase (PfPI4K) as the target of a class of experimental antimalarial drugs called the imidazopyrazines, which has the potential to prevent, block and treat multiple stages of the malaria lifecycle. The research is supported by the Wellcome Trust and Medicines for Malaria Venture.

While current treatments for malaria are mostly effective, there have been reports that the efficacy of artemisinin-derivatives has been compromised in parts of South-East Asia. Moreover, antimalarial therapies are only effective against the acute blood stages of the disease, thus leaving some patients at risk of relapse after initial treatment, especially those infected with P. Vivax.

"Our scientists carried out a large phenotypic screen which, coupled with modern genome analysis and editing tools, constitute a powerful technology platform to discover and validate drug targets for next-generation antimalarial drug discovery," said Martin Seidel, institute director of the Genomics Institute of the Novartis Research Foundation (GNF), in a press release.

They then isolated strains of parasites that had become resistant to the compound class and identified the mutated genes. For one of these genes, PfPI4K, they went on to show through biochemical experiments that imidazopyrazines work through interaction with the ATP-binding pocket of the kinase. They also showed that these compounds are active against blood-stage field isolates of the major human malaria pathogens, P. falciparum and P. vivax, and inhibit liver-stage hypnozoites of a parasite P. cynomolgi, which is closely related to P. vivax.

Source: Novartis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here